Physician profile

Hesham Morsi

Neuroradiology · Boise, ID

NPI 1104864461

$2,356.10

in general payments reported to CMS, 2019-2025

9 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$315.08

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Penumbra, INC. $1,523.28 2019-2023 Red 72
Microvention, INC. $250.42 2019
Imperative Care, INC $129.47 2023 Zoom 88-T Large Distal Platform, Zoom Reperfusion Catheter
Genentech USA, INC. $119.03 2019
Medical Device Business Services, INC. $118.29 2019
Medtronic USA, INC. $92.31 2019-2020
Depuy Synthes Sales INC. $66.56 2020
Stryker Corporation $37.59 2023 Trevo, Surpass Evolve
Janssen Pharmaceuticals, INC $19.15 2020

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Hesham Morsi

$2,356.10

in general payments reported 2019-2025

Years
2019-2023
Top company
Penumbra, INC.

https://glasscript.com/doctor/49557/hesham-morsi

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.